Lisa M. Coussens

Lisa M. Coussens

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Lisa M. Coussens

Oregon Health & Science University 2 Department of Cell, Developmental and Cancer Biology Portland, Oregon

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2018 in Science
Verified
Journal Article
Closed access
PDF file
VGVancheswaran Gopalakrishnan
Vancheswaran Gopalakrishnan
CSC. N. Spencer
C. N. Spencer
LNLuigi Nezi
Luigi Nezi
Alexandre ReubenAlexandre Reuben
Alexandre Reuben
MAMiles C. Andrews
Miles C. Andrews
JWJennifer A. Wargo
Jennifer A. Wargo
Good bacteria help fight cancer: Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32

1 April 2015 in Cancer Cell
Verified
Journal Article
Closed access
BRBrian Ruffell
Brian Ruffell
LCLisa M. Coussens
Lisa M. Coussens

18 March 2022 in Science
Verified
Journal Article
Closed access
DCDavid Crosby
David Crosby
SBSangeeta Bhatia
Sangeeta Bhatia
KBKevin Brindle
Kevin Brindle
LCLisa M. Coussens
Lisa M. Coussens
CDCaroline Dive
Caroline Dive
SBShankar Balasubramanian
Shankar Balasubramanian
Survival improves when cancer is detected early. However, ~50% of cancers are at an advanced stage when diagnosed. Early detection of cancer or precancerous change allows early intervention to try to slow or prevent cancer development and lethality. To achieve early detection of all cancers, numerous challenges must be overcome. It is vital to better understand who is at greatest risk of developing cancer. We also need to elucidate the biology and trajectory of precancer and early cancer to identify consequential disease that requires intervention. Insights must be translated into sensitive and specific early detection technologies and be appropriately evaluated to support practical clinical implementation. Interdisciplinary collaboration is key; advances in technology and biological understanding highlight that it is time to accelerate early detection research and transform cancer survival.

1 November 2014 in Cancer Cell
Verified
Journal Article
Closed access
BRBrian Ruffell
Brian Ruffell
DCDebbie Chang-Strachan
Debbie Chang-Strachan
VCVivien Chan
Vivien Chan
ARAlexander Rosenbusch
Alexander Rosenbusch
CHChristine M.T. Ho
Christine M.T. Ho
LCLisa M. Coussens
Lisa M. Coussens

18 January 2013 in Science
Verified
Journal Article
Closed access
PDF file
LCLisa M. Coussens
Lisa M. Coussens
LZLaurence Zitvogel
Laurence Zitvogel
APA. Karolina Palucka
A. Karolina Palucka
A Shift in Cancer's Inflammatory Balance: One of the many factors that contribute to the initiation and progression of cancer is inflammation. Inflammation can support tumor development, both directly and indirectly, and tumors can promote a chronic inflammatory environment that results in immunosuppression, which benefits the tumor. Coussens et al. (p. 286 ) review the components of the immune system that contribute to the chronic inflammation seen in tumors. Potential therapies might shift this inflammatory environment toward one more characteristic of an acute, resolving inflammation, similar to what is observed during a pathogenic infection. Such a shift would relieve immunosuppression and drive antitumor immunity that, when combined with other therapies, may ultimately result in tumor cell clearance.

1 March 2016 in Cell
Verified
Journal Article
Closed access
APA. Karolina Palucka
A. Karolina Palucka
LCLisa M. Coussens
Lisa M. Coussens